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Abstract
The increasing size and complexity of exome/genome sequencing data requires new tools for clinical geneticists
to discover disease-causing variants. Bottlenecks in identifying the causative variation include poor cross-sample
querying, constantly changing functional annotation and not considering existing knowledge concerning the
phenotype. We describe a methodology that facilitates exploration of patient sequencing data towards
identification of causal variants under different genetic hypotheses. Annotate-it facilitates handling, analysis and
interpretation of high-throughput single nucleotide variant data. We demonstrate our strategy using three case
studies. Annotate-it is freely available and test data are accessible to all users at http://www.annotate-it.org.
Background
Context
With the advent of massively parallel high-throughput
sequencing technologies and the increasing availability of
reference genomes, new opportunities emerge for disco-
vering genome-wide variation across individuals and
populations, at both the large-scale level (deletions,
duplications, and rearrangements) and the base-pair level
(single nucleotide variants and small indels and repeats).
As more and more sequence data are produced, accurate
assessment of the frequency of variants in specific subpo-
pulations (patients versus controls or any phenotypically
different populations) is vital to the interpretation of how
these variants segregate across populations. International
projects, such as the 1000 Genomes Project [1] and the
Hapmap Project [2], have been set up to assess the
genetic variation across large groups of ‘normal’ human
individuals. Full-genome [3], whole-exome [4-6] or tar-
geted gene panel [7,8] sequencing studies of individuals
struck by Mendelian disorders can aid in identifying the
genetic cause for these diseases; for example, by lever-
aging publicly available data, under the assumption that
these rare variants do not occur in the normal popula-
tion. Furthermore, trio sequencing of an affected child
and of his or her parents can identify de novo variants in
sporadic cases of genetic disease [9,10].
Because of the large size and complexity of next-
generation sequencing data sets, new computational and
statistical methods for analyzing and interpreting the
data are required to accurately find the variation of biolo-
gical interest. To transform raw sequencing data into var-
iation data, we need to undertake the following steps:
(1) sequence alignment, (2) variant calling, (3) variant
annotation, and (4) variant interpretation [11,12]. In this
study, we mainly focus on the latter two steps. After
sequence alignment and variant calling, we end up with a
list of variants with their genomic coordinates and the
variant alleles that differ from the reference sequence.
Based on current knowledge of functional elements
annotated in the human genome sequence, overlapping
variants within the annotated features are found and the
impact on RNA and protein sequence level is computed.
Variant lists can be reduced further by applying func-
tional impact prediction tools, such as Polyphen2 [13],
SIFT [14], FoldX [15], and others [16]. Such tools
are computationally intensive and require dedicated
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computing infrastructure to run variants in a high-
throughput automated fashion. To tackle this problem,
precomputed whole-genome predictions for popular
tools are available in Ensembl and in dedicated databases
[17]. Aggregated functional impact scores, such as
CAROL [18], are also useful as these usually perform bet-
ter in classification benchmarks for disease-causing
mutations but are often not provided by current annota-
tion tools.
These annotated variants can then further be interpreted
by filtering based on either quality, functional, or genetic
criteria. These filtered annotated data are then interpreted
by either collapsing the data into the desired functional
units, often genes, or performing formal statistical associa-
tion analysis methods [19].
Several software tools have already been developed to
tackle the aforementioned analysis steps. Some of these
tools, such as ANNOVAR [20], TREAT [21], VarioWatch
[22], SeqAnt [23], and Anntools [24], have been specifi-
cally designed to handle the annotation task and use
diverse data sources in order to achieve this (Table 1).
Other tools focus solely on the interpretation step and
facilitate tasks such as easy filtering of data (VarSifter
[25]), ranking based on putative pathogenicity (Var-MD
[26]) or do more complex types of analysis by performing
association analyses or looking at different underlying
genetic disease models (VAAST [27]). A variety of tools
try to be more comprehensive and provide a streamlined
approach by tackling both steps (KGGSeq [28], SVA [29]).
Although current tools have matured significantly, they
still possess several limitations. First there is the ‘red
queen’ annotation problem. As functional information is
constantly evolving, end users are forced to keep data
sources and variant annotation up to date with every
release of new information. Although some annotation
tools make it easy to update annotation sources, this can
still be a problem when trying to use previously acquired
data sets in a related setting without repeating the com-
plete annotation process. Secondly, interpretation is
often done at the level of the individual sample, whereas
cross-sample analysis is often left to the end user. This
requires computational expertise when dealing with large
data sets. Additionally different biological contexts might
require a different combination of analysis techniques
(that is, case/control studies versus familial or trio stu-
dies). Also, these analysis techniques are often pheno-
type-naive and disregard existing a priori biological
knowledge of the particular disease or phenotype under
study. Thirdly, when working in a collaborative setting,
keeping track of individual files, annotation versions, and
variants can prove difficult and easy sharing of variation,
validation, sample, and experiment metadata is usually
crucial. This is especially the case in the analysis of
Mendelian disorders where cases are often spread glob-
ally across research institutions.
Aim
To tackle these hurdles, we developed a framework,
called Annotate-it, that provides experimentalists with a
Swiss-knife approach for the interpretation of single-
nucleotide variants, providing features such as automated
annotation, prioritization of mutated genes, cross-sample
querying and data management. We expand on existing
comprehensive annotation and interpretation frame-
works by integrating more annotation sources and differ-
ent established state-of-the-art analysis techniques. We
also integrate two different gene prioritization techni-
ques: AGeneApart [30] and Endeavour [31]. AGeneApart
mines MEDLINE abstracts to discover known genes or
potentially new genes linked to the phenotype whereas
Endeavour ranks genes based on similarity profiling com-
pared to known disease genes. The latter method is more
suitable for finding novel disease genes as it does not
require a direct relationship between gene and disease
[32]. These methods allow us to rank mutated genes tak-
ing the phenotype into account. Finally, because of its
web-based interface, we allow for a collaborative work-
flow and the management of shared or public data, as
well as a wide range of visualizations.
Implementation
Annotation and filtering methodology
Multiple annotation sources are supported, which can be
classified into gene level and variant level information.
Genes are annotated using Gene Ontology [33] terms,
Online Mendelian Inheritance in Man (OMIM) and hap-
loinsufficiency predictions [34]. We also provide pathway
information from KEGG [35], BIOCARTA, and Reac-
tome [36], as well as protein-protein interaction and pro-
tein complex data from STRING [37] and the Corum
project [38]. Additionally, we provide statistical phenoty-
pic associations with known chromosomal aberrations
and phenotypic ontologies based on text-mining of
recent MEDLINE releases [30]. Tissue-based expression
information from the eGenetics/SANBI data set is also
included to search for genes that are expressed in parti-
cular tissues of interest.
Information on the individual variants include Phast-
Cons and Phylop scores (for primate, placental mammal
and vertebrate multiple alignments) and presence in
dbSNP, 1000 Genomes Project, and the 200 publicly
available Danish exomes [39]. Also functional impact
prediction scores from SIFT [14], Polyphen2 [13], LRT
[40], and MutationTaster [41] are extracted from
dbNSFP [17]. An aggregate score of SIFT and Polyphen2
is also computed with CAROL [18], which has been
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demonstrated to perform better than individual scores at
predicting deleteriousness of nonsynonymous variants.
Annotate-it has a flexible query system that allows
answering complex cross-sample questions in an easy
and quick way without any need for computational
expertise. Using this interface, users can quickly check
different inheritance hypotheses (for example, recessive
or dominant models, or de novo occurrence of variants
in parents-child trio analysis) depending on the available
familial information. It also permits filtering based on
consequence type, minimum and maximum coverage,
minimum and maximum variant allele frequency, het-
erozygosity call, presence in dbSNP, 1000 Genomes Pro-
ject, the NHLBI exome variant server and 200 Danish
Table 1 Comparison of features of different tools for next-generation sequencing annotation and interpretation













Command line Web Web Web
Indels x x x x x x x x
SNPs x x x x x x x x x x x
miRNA annotation x x x
Regulatory region
annotation




Gene annotation x x x x x x x x
Conservation
scores
x x x x x
LRT x x x
MutationTaster x x x
Polyphen2 x x x x
SIFT x x x x x




OMIM x x x x




1000 Genomes x x x x x x x x
dbSNP x x x x x x x x
Gene prioritization x
Literature retrieval x x x




x x x x x
Gene expression x x
Statistical analysis x x x
Filter x x x x x x x
Complex filtering
rules
x x x x
Cross-sample
querying




x x x x x x x
Data sharing x
Visualizations x x x x x
OMIM, Online Mendelian Inheritance in Man; PPI, protein-protein interaction.
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exomes, variants present in other samples, and conserva-
tion scores (Additional file 1). Annotate-it also allows
screening a user-defined (or automatically generated)
panel of genes of interest. Ultimately, these filtering steps
will result in a list of genes (or exons) ordered by user-spe-
cified criteria (for example, present in given number of
samples, number of unique alleles) (Additional file 2).
Genes can then be further inspected by consulting all the
available information that Annotate-it aggregates. This
information contains associated phenotypes, automated
literature retrieval, links to OMIM, region-based conserva-
tion plots, STRING or protein complex interaction part-
ners and gene ontology terms (Additional file 3).
Interpretation and statistical analysis
In addition to the widely used collapsing method of dis-
ease-gene discovery, where variants across affected sam-
ples are collapsed at the gene level and counted, the user
can also perform formal statistical analysis using the
methodology proposed by Ionita-Laza for case/control
studies [19]. This type of statistical methods has the
added benefit of computing an approximate P-value for
individual genes and of taking into account inherent
background variation in genes due to factors such as
gene size or hypermutable regions. However, they do
require a significant amount of control samples in order
to reach satisfying statistical power (n > 50). The analysis
can be applied directly on the imported data without any
reformatting or performing any command line actions.
The user can also provide a particular phenotype using
Human Phenotype Ontology terms that can be used to
derive genome-wide rankings produced by AGeneApart
and Endeavour. These rankings are precomputed for all
Human Phenotype Ontology terms for which at least five
gene-phenotype associations are known, which can be
used as a training set for the prioritization algorithm.
Furthermore the user can investigate mutation patterns
of interaction partners of genes of interest. This is
achieved by integrating the STRING and CORUM pro-
tein-protein interaction networks. This can be of particu-
lar interest when the cause of disease is expected to be
oligogenic, such as diseases with some degree of phenoty-
pic variability.
Metadata and collaboration
Additional metadata can be linked to samples and experi-
ments. Samples are entities within experiments and can
contain phenotypic information from different integrated
ontologies (for example, European Paediatric Cardiac
Code [42], London Dysmorphology Database [43],
Human Phenotype Ontology [44]), gender, the date of
sequencing, batch number, and other data. Metadata
allow organizing and querying samples across multiple
experiments. The experiments themselves can also store
metadata, such as the software and parameters used for
alignment and variant calling. Within an experiment, var-
iants can be marked for validation, and validation infor-
mation can be stored and reviewed. Promising candidate
genes can be organized into gene lists when dealing with
many collaborators or complex study setups. Gene lists
can also be used as masking filters to either study gene
specific gene panels or exclude sets of genes that are not
of interest. An experiment-wide permission system with
different roles (owner, editor, user) allows collaboration
amongst different researchers and also allows the public
sharing of data.
Visual analytics
Visual analytics is gaining ground for data exploration in
the context of big data. The integrated interactive graphi-
cal filter (Figure 1) visualizes the different distributions of
variants (for example, coverage, consequence types, con-
servation scores, variant allele frequency) and shows the
impact of different filtering thresholds in real time, allow-
ing selection of optimal thresholds. This is particularly
useful in an exploratory phase to get a grasp on the char-
acteristics of the data set and on how filter settings will
affect these characteristics. Once optimal thresholds have
been selected, they are easily applied in a subsequent dis-
covery phase where the main goal is to select candidate
genes of interest.
Calculating statistics for such large data sets in real-time
is computationally taxing; therefore, Annotate-it’s interac-
tive filter can currently only be run on a subset of the var-
iants (maximum 200,000 variants). Further research in the
development of advanced data structures and browser
infrastructure is needed to cope with the running time
complexity of these approaches. As user interaction and
feedback increases, we aim to optimize the informative
value of such interconnected graphs and to improve the
throughput of these visualization techniques.
Technical specifications
Annotate-it is programmed in the Ruby programming
language and makes use of the Ruby on Rails framework
[45] for its web interface. Currently, Annotate-it supports
both hg18 (NCBI36) and hg19 (NCBI37) genomic builds.
The annotation process leverages existing libraries, such as
the Ruby Ensembl-API [46] and BioRuby [47], to enable
programmatic access to locally run mirrors of the latest
Ensembl [48] versions for any given genomic build.
MySQL [49] was chosen to store variant information in
a database. Nevertheless, Annotate-it’s architecture is
completely technology independent and therefore switch-
ing to different Rails-supported databases requires little
effort. For large data sources containing billions of data
points (such as base-wise conservation scores), we rely on
Tokyo Cabinet [50] key-value stores for quick access.
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Interactive visualizations were implemented using Proces-
sing [33] and integrated into the web-interface as java
applets.
Computationally intensive tasks (for example, complex
predictions based on protein structure analysis) can be
accomplished in a distributed manner by installing the
Annotate-it client and the software one wishes to run on
any computing node that has direct network access to the
Annotate-it server. In this way, computing power can be
scaled up on demand, either locally or by the use of cloud-
based systems. Variant files can be uploaded and imported
in the correct data structures at a pace of 500 variants per
second using the current computing infrastructure.
Previously unseen, and thus yet unannotated, variants are
processed at a rate of approximately 85 variants per
second. Computing infrastructure can be easily expanded
to face increasing demand using elastic cloud technologies.
This process is run completely at the server-side and
requires no user interaction.
Input files of different formats are supported. So far,
support includes Varscan [51], Atlas-SNP2 [52], Samtools
[53] variant calling format, Genome Analysis Toolkit’s
VCF4 [54], Roche 454 GSMapper, and Illumina CASAVA
output. Multiple files of different formats or sequencing
technologies can be transparently combined for a single
sample. Gene and variant lists can be exported to tab-
separated value files based on the used filter-settings if
needed.
Generation of Miller syndrome semi-synthetic data sets
We generated synthetic data sets of Miller syndrome by
taking the following steps. We selected eight unrelated
Figure 1 Screenshot of interactive graphical filter. (a) In Annotate-it, the graphical interactive filter allows the user to view the distributions
of a number of parameters and interactively set filter settings. Filters can be adapted by dragging thresholds or clicking to select/deselect
certain types of variants. Filtering on one parameter shows the impact on all other parameters in near real time. Plots included at the time of
writing are (clockwise starting from upper left) coverage, variant allele frequency, presence in public databases, Phylop scores, the number of
candidate genes hit in a given amount of samples, and Phastcons scores. Once satisfied the user can apply the filter settings and inspect the
resulting gene lists. (b, c) Zoomed in portions of the interactive filter show a bar plot showing the proportions of variants of different
consequence types (b) and the distribution of conservation scores for (red) primates, (blue) mammals, (green) vertebrates (c).
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previously acquired exomes sequenced by Illumina GA2
and Illumina HiSEQ 2000. We aligned these exomes with
BWA and called variants using the Genome Analysis
Toolkit pipeline, both at default settings (Table 2). The
sample identifiers of the variants were then randomly
shuffled, maintaining the total number of variants, the
number of variants per individual exome and the number
of variants of each consequence type in the randomized
data set (Figure 2). The eight synthetic exomes were then
randomly assigned to either case or control groups so
that each group contained four samples. Mutations
found in the four published Miller syndrome cases were
then added to each of the respective synthetic case sam-
ples. This synthetic case-control data set was then ana-
lyzed with Annotate-it using the following filter settings:
minimum 10× coverage, minimum variant allele fre-
quency of 20%, only ‘novel’ variants, variants not found
in the 1000 Genomes Pilot project, and variants not
occurring in the control samples. Only nonsynonymous,
nonsense or essential splice site variants were considered.
Ranking of the candidate genes was done based on the
number of case samples in which the gene was consid-
ered a hit and the Phylop conservation score based on
the multiple alignment of placental mammals. We calcu-
lated rank statistics based on 1,000 randomizations fol-
lowing the previous steps.
Results
We validated the use of Annotate-it using three indepen-
dent datasets: 1) a semi-synthetic Miller syndrome
dataset, 2) a Schinzel-Giedion syndrome dataset and 3)
a Nicolaides Baraitser syndrome dataset. In Miller syn-
drome as in Schinzel Giedion syndrome the causative
gene was previously discovered and thus served to see if
results could be reproduced using Annotate-it. Due to
the synthetic nature of the Miller syndrome set we were
able to statistically estimate the efficiency of commonly
used filtering approaches in the discovery of Mendelian
disease genes. In the Nicolaides Baraitser syndrome data-
set the causative gene was previously unknown to us and
illustrates how additional phenotype-specific information
can aid in the discovery of causative genes.
Case study 1: semi-synthetic Miller syndrome data
To evaluate the impact of random neutral variation on
finding the causative gene, we generated a synthetic data
set modeled on published cases of Miller syndrome [5], a
rare recessive disease caused by mutations in DHODH.
We considered two possible genetic models, which have
been implemented in Annotate-it, when computing the
rank of DHODH: the recessive model, meaning that a gene
was only considered a hit in a sample if two different var-
iants were found (assuming that a causal homozygous non-
reference variant was highly unlikely), and the dominant
Table 2 Statistics of initial exomes used for randomizations
Sample identifier
Sample identifier 1 2 3 4 5 6 7 8
Platform GAII GAII GAII GAII HiSEQ HiSEQ HiSEQ HiSEQ
Essential splice site mutations 178 120 137 134 47 45 49 44
Nonsense mutations 99 88 95 108 101 60 68 68
Nonsynonymous mutations 8,864 7,468 8,039 8,246 7,925 6,715 6,487 6,560
Synonymous mutations 8,409 7,214 7,756 8,065 8,500 7,676 7,347 7,597
UTR mutations 3,839 3,216 3,080 3,264 4,264 1,443 1,421 1,367
Eight previously acquired exomes were used to generate 8,000 synthetic exomes by randomization. The initial exomes were sequenced by either Illumina GA2 or
Illumina HiSeq 2000, then aligned with BWA and variants were called using the GATK pipeline.





























Figure 2 Randomization scheme used for the semi-synthetic
Miller data set. We started from eight non-related previously
acquired exome sequences and shuffled the sample identifiers
linking a variant to a sample. By doing this the total number of
variants and the number of variants per consequence was kept
constant but the constitution of each of the exomes changed
continuously. We then assigned four exomes to both control and
case groups. In the case group we added two of the reported
causal variants to each of the case samples. We then analyzed each
of the randomizations with Annotate-it and looked at the resulting
rank of DHODH. By repeating this randomization cycle 1,000-fold we
calculated rank statistics.
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model. Under the recessive model an average of 16 (± 2)
candidate genes with hits in the 4 patients (41 (± 4), 105
(± 6),417 (± 12) candidate genes with hits in at least 3, 2, or
1 patient, respectively) were found. Out of these candidate
genes, DHODH ranked in the top two in 95% of the rando-
mizations (Figure 3). Under the dominant model an aver-
age of 113 (± 7) candidate genes with hits in the 4 patients
(408 (± 12), 1132 (± 15),3417 (± 15) candidate genes with
hits in at least 3, 2, or 1 patient, respectively) were found.
Out of these candidate genes, DHODH ranked in the top
seven in 95% of the randomizations. These data show that,
despite random neutral variation, simple filtering and sort-
ing criteria can dramatically decrease the number of genes
to be validated in the case of Mendelian disorders.
Case study 2: Schinzel-Giedion syndrome
In a study by Hoischen et al. [55] exome sequencing was
used to identify causative mutations in Schinzel-Giedion
syndrome. Because of the rarity of the disorder, the
absence of gender bias, its mostly sporadic occurrence and
the absence of cytogenetic imbalances, the disorder was
believed to be caused by variants in a single or perhaps a
few genes resulting in an autosomal dominant inheritance
pattern. Exome sequencing of four patients, and validation
in an additional four patients by Sanger sequencing, has
identified de novo mutations in SETBP1 to be causative for
the disease. These mutations were clustered in a highly
conserved region of the gene and are found in an 11-bp
stretch. In the previous study, mutations were filtered
based on dbSNP build 130 for novel variants and only
nonsynonymous (mutations changing the amino acid
composition of the protein), nonsense (mutations resulting
in either a gain or loss of a stop codon) or essential splice
site variants (mutations located within two bases of the
intron/exon boundary) were considered. Previously gener-
ated in-house data were used to filter out variants found
in samples not related to the phenotype. This was done
under the assumption that because of the rarity of the dis-
order, it was unlikely that these control samples would
contain the same causal variant.
We reanalyzed the data using Annotate-it and applied
default filters to validate the effectiveness of our methodol-
ogy. We uploaded the variant files for annotation on the
hg18/NCBI36 build of Annotate-it and filtered variants
using two different settings: a cross-sample comparison at
the gene level and a comparison at the exon level. The
only major difference between both strategies is that
instead of looking for candidate genes hit by variants
across the patients, in the second approach we also look
for specific exon hits across patients. For both strategies,
we filtered out variants present in dbSNP (build 130) and
the 1000 Genomes Project pilot studies (July 2010 release).
We only selected variants with nonsense, nonsynonymous,
and essential splice site consequences. We did not set any
further filters, so as to recreate the scenario in which no
further information was available to the researcher. Even
though stricter filter settings would reduce the size of the
resulting gene lists, we decided that manual inspection of
all available information would allow us to select potential
candidate genes without filtering a priori and potentially
suffering false negative results that could lead to missing
the implicated gene.
Both filtering approaches resulted in either a list of
11 candidate genes hit across the 4 patients (or 30, 91, 793
candidate genes in, respectively, at least 3, 2, or 1 patient)
or 13 candidate exons across the 4 patients (or 38, 81, 840
candidate exons in, respectively, at least 3, 2, or 1 patient).
Sorting the gene list on number of samples implicated and
maximum Phylop scores for placental mammals in the
found variants, SETBP1 ranked at the top of the list as the
prime candidate (Table 3). Further inspection of SETBP1
revealed the cluster of variants in a highly conserved
region in the graphical view (Additional file 4), which
might be indicative of gain-of-function mutations. Other
genes that were hit across the four samples were also
found but were deemed less likely because of either being
hypervariable (for example, CDC27) or having variants in
regions of lower conservation. In the exon-based approach
one of the SETBP1 exons was ranked in the top ten exons
hit across the four patients. Other high ranking exons
were deemed unlikely candidates because of the high
number of variants found and were likely hypervariable
regions or pseudogenes. This approach is theoretically
more sensitive to distinguish causative exons, as neutral





























Figure 3 Rank statistics for DHODH based on 1,000
randomizations. The x-axis indicates the rank of DHODH, the y-axis
indicates the cumulative probability of observing a rank lower than
that marked on the x-axis.(red) Under the recessive model DHODH
ranked in the top two candidate genes in 95% of the
randomizations. (blue). Under the dominant model DHODH ranked
in the top seven in 95% of the randomizations.
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variation is less likely to be clustered in individual exons
across samples, even though it remains susceptible to the
previously mentioned regions of increased variability.
Case study 3: Nicolaides-Baraitser syndrome
Additionally we used Annotate-it to unravel the etiology
of the previously unsolved Nicolaides-Baraitser syndrome
(NBS) [56]. NBS is characterized by intellectual disability,
sparse hair, distinctive facial characteristics, and distal-
limb anomalies. The extremely rare sporadic recurrence
of the disease and the lack of bias towards any gender
suggested the cause of the disease to likely be autosomal
dominant de novo mutations. We collected DNA from
four unrelated cases and performed whole-exome
sequencing. We ran the analysis in Annotate-it using
default filters and parameters (nonsense, splice site, and
nonsynonymous mutations not present in any of the
available population databases). This resulted in a list of
296 candidate genes sorted based on the number of sam-
ples having mutations in the given gene and the number
of mutations pertaining to a single sample for that gene.
The top ranked gene, ACVR2A, was the only candidate
gene with variants present in the four samples containing
the same variant. Recurring mutations are more likely to
be population-specific polymorphisms, and thus not
captured by aspecific population databases, than de novo
variation, which is believed to randomly occur through-
out the genome and therefore has a very low probability
of mutating the same position four times in non-consan-
guineous individuals. The second best ranking gene,
SMARCA2, contained unique heterozygous nonsynon-
ymous mutations in three of the four samples. Further
investigation of associated gene ontologies and associated
phenotypes computed by AGeneApart revealed this gene
to be involved in chromatin remodeling and facial
abnormalities, making it an interesting candidate for
validation. Sanger sequencing of the samples and their
respective parents revealed the three variants to be de
novo events. Additional resequencing of SMARCA2 in
44 individuals revealed heterozygous mutations in the
same carboxy-terminal helicase domain in 36 patients,
hereby validating SMARCA2 as the causative gene for
Nicolaides-Baraitser syndrome. Later published studies
discovered the etiology of the phenotypically related Cof-
fin-Siris syndrome to be caused by similar mutations in
SMARCB1 and ARID1B, which are direct interaction
partners of SMARCA2 in the SWI/SNF chromatin remo-
deling complex [57,58]. Based on these findings we
added functionality to Annotate-it to find causative
mutations in protein complexes rather than in a strictly
monogenic setting. By doing this we discovered that one
of eight patients diagnosed with NBS for which we per-
formed whole-exome sequencing carried a mutation in a
gene identified in Coffin-Siris syndrome. Although the
phenotype of NBS is strongly overlapping with that of
Coffin-Siris syndrome, the latter differs by the presence
of hypoplastic or absent fifth finger nails with or without
hypoplasia of the terminal phalanges, the absence of
swelling of the finger joints, short metacarpals and broad
terminal phalanges and internal organ malformations are
more common. Yet due to the large overlap of features,
both syndromes are hard to classify [59], especially at a




A multitude of publicly available computational tools exist
in order to assist bioinformaticians and geneticists by facil-
itating the analysis of single nucleotide variants at the level
of annotation, interpretation or both. Yet most tools focus
only on particular aspects of the analysis pipeline (Table 1)
Table 3 Top ten candidate genes in the Schinzel-Giedion case study










1 SETBP1 4 2 3 0.721 3.455
2 CDC27 4 5 13 - 3.106
3 CTBP2 4 3 8 - 2.805
4 PRB1 4 2 5 - 1.458
5 KIR2DL1 4 1 2 - 1.05
6 FLG 4 5 6 - 1.034
7 OR11H1 4 0 1 - 0.856
8 KIR2DL3 4 4 6 - -0.326
9 CDCP2 4 0 1 - -0.365
10 NBPF12 4 0 2 - -0.411
The data were analyzed using Annotate-it. Genes were considered a hit if they contained either nonsynonymous, nonsense or essential splice site variants that
were not present in dbSNP or found in the 1000 Genomes Project. Genes were then sorted based on number of affected samples in which the gene was a
candidate and conservation in placental mammals. Additionally, the total number of variants present across all samples and the number of variants unique to
only one sample is given.
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and are thus only usable under certain experimental cir-
cumstances. Furthermore, all described tools suffer from
several drawbacks, such as ‘red queen’ annotation pro-
blems, cross-sample analysis, phenotype-naive interpreta-
tion and general data management problems, such as data
compatibility and data sharing [60].
Annotate-it
In this paper, we describe Annotate-it, a versatile frame-
work for the analysis of multisample single nucleotide sub-
stitution data generated by next-generation sequencing.
Annotation of samples is performed on the server side,
eliminating the need for the installation of complex tools
and annotation sources by the end-user and automatically
keeping those annotations up to date.
The query and filtering interface enables the geneticist
to quickly test different genetic hypotheses (recessive,
dominant, de novo) across multiple samples and aggre-
gates available information at the gene and variant level,
facilitating the manual revision of candidate gene lists. We
also provide a suite of more complex analysis techniques,
such as aggregate functionality scores, phenotype-specific
gene prioritization, and statistical methods for disease-
gene finding in case/control studies without any need for
data reformatting or computational expertise. By merging
different state-of-the-art analysis techniques we aim to
deliver a Swiss-knife type tool that can be used in many
different experimental contexts. By unifying the interface
and centralizing the data the user is able to perform multi-
faceted analyses without any need for additional data
management or formatting and without requiring any
computational expertise.
Case studies
To validate our approach we simulated an experiment
with randomized exomes and published variants found in
Miller syndrome patients. We computed ranking statis-
tics showing that the causative gene ranks highly, even
with a large amount of random neutral variation. This
happens even when considering a relatively small set of
patient exomes. In a second benchmark, we reanalyzed a
published case study of the Schinzel-Giedion syndrome
and identified the causative gene, SETBP1, as the top-
ranked gene, using default parameters. Further inspection
reinforced the previous finding that novel nonsynon-
ymous variants across patients are clustered in a small
11-bp stretch. We applied the same approach in a pre-
viously unpublished study of NBS and found SMARCA2
as one of the top-ranking genes. This gene was then
further validated to be the causative gene in this disease.
Furthermore, we show in this case that gene prioritiza-
tion methods can aid in the prioritization of mutated
candidate genes by linking these genes to their associated
phenotypes. Additionally, we show that in phenotypically
overlapping disorders, leveraging protein-protein interac-
tion data could prove useful in deciphering neighbor-
hoods of mutated genes.
Future perspectives
Although the framework as presented here is fully able to
support the discovery of causal genes of rare genetic disor-
ders, our approach would benefit further from several cri-
tical features that we will investigate in future work. First,
the confidentiality of human clinical data is a concern of
many clinical geneticists and is still a topic of debate in
most research centers. We aim to develop future releases
of Annotate-it using a client-server architecture, so that
sample and genotype information is dealt with on a locally
installed client that automatically synchronizes genomic
(but not clinical) data (that is, single nucleotide variant
chromosome, position, and variant allele) with a server
that holds the most up-to-date annotation information.
A public client will be available for sharing data across
research centers. Secondly, we designed Annotate-it with
protein coding single-nucleotide substitutions in mind as
proof-of-concept. We aim to further expand the scope of
the methodology to encompass annotation of non-coding
regions and other types of variation, such as insertions and
deletions of varying lengths.
Conclusions
In this paper we describe the application of Annotate-it
to study rare monogenic Mendelian disorders caused by
rare, highly penetrant variants in the population. Because
sequencing (as opposed to classical array-based genome-
wide association studies) detects rare (less than 0.01% of
the general population), infrequent, and frequent variants
(over 1%), extensions of our strategy will be useful in
resolving oligogenic diseases caused by a combination of
infrequent variants of intermediate penetrance. Discover-
ing the disease genes in such challenging cases will
require good models of (1) the underlying population
genetics (to avoid confounding effects from population
structure), (2) the functional impact of variants on pro-
tein function and on regulation (to weed out passenger
mutations), and (3) the biological pathways involved (to
detect causative variants through their effect on pathways
rather than individual genes). This is a primary research
goal for the near future.
Current approaches to identifying causal variants by
patient sequencing, including ours, can reliably interpret
only the most straightforward subset of the variome
(nonsense, missense, and splice-site variants). For exam-
ple, synonymous variants, variants in regulatory, intronic,
and intergenic regions, and variants in microRNAs
remain highly challenging. Future experimental and in
silico studies assessing the impact of such variants will
allow us to develop computational strategies to bridge
Sifrim et al. Genome Medicine 2012, 4:73
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the gap in data interpretation between the exome and the
complete genome. In particular, refinements in the map-
ping of regulatory regions and other functional elements
through functional studies, evolutionary conservation,
and in silico models will be essential to enable variant
interpretation beyond the coding exome. Furthermore,
the integration of large-scale structural variation will be
crucial in a comprehensive study of the variome. Such
integration will be challenging because structural varia-
tion inherently requires different types of data structure,
visualization, and analysis methods. A high-level meta-
analysis of variation at multiple scales should provide
researchers with a complete picture of individual gen-
omes. Making such complex, integrative analyses effec-
tive is a major challenge for the computational biology
community.
Given the positive reactions from initial users, we believe
that Annotate-it can play a significant role in the prioriti-
zation and identification of candidate genes in Mendelian
disease. In the future, we aim at broadening its scope by
increasing the annotation information available, the effec-
tiveness and scope of our filtering analysis methods, and
the robustness and ease of use of our web interface.
Availability
Annotate-it is freely available at [61]. Bug reports can be
made and feedback accessed at [62].
Requirements
Annotate-it has been tested on the following browsers:
Google Chrome (build 11.0.696.71 or later), Mozilla
Firefox (version 3.6 or later), Safari (version 5.0 or later).
Microsoft Internet Explorer is currently not supported.
Additional material
Additional file 1: Screenshot of Annotate-it’s filter settings pane.
Through the web interface the user can easily analyze imported data
sets through a simple point and click interface. Samples can be easily
added or excluded from the analysis. Filter settings such as minimum
coverage, presence in dbSNP and 1000 Genomes Project and uniqueness
can be applied and different sorting schemes can be devised and then
applied on the selected samples.
Additional file 2: Screenshot of Annotate-it’s gene list view. After
selecting samples to be analyzed and filtering and sorting criteria a
resulting gene list is outputted. This gene list contains information on
the amount of selected samples containing unfiltered variants and
conservation scores. A tab with distribution plots is also provided (not
shown here). Genes in this list are clickable and doing so returns more
gene- and variant-specific information for that respective gene
(Additional file 3).
Additional file 3: Screenshot of Annotate-it’s gene details view.
Mutated genes can be further inspected to show additional information
such as gene ontology, publications, associated pathways, associated
phenotypes through gene prioritization, interaction partners (and their
mutations) and involved protein complexes (and their mutations). Also
detailed information on the mutations contained in that gene is given.
Additional file 4: Screenshot of Annotate-it’s gene view
visualization. This visualization shows the clustering of variants in an 11-
bp stretch of a single highly conserved exon of SETBP1 between position
40783844 and 40787303. Conservation scores are given for the complete
exon on the primate, mammal and vertebrate level. Nonsynonymous
mutation are marked as light blue circles each belonging to one of the
four patients (with sample identifiers 40816, 43664, 48062, 54126).
Abbreviations
bp: base pair; NBS: Nicolaides-Baraitser syndrome; OMIM: Online Mendelian
Inheritance in Man; SNP: single nucleotide polymorphism.
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